US 12,168,070 B2
Transmucosal and transdermal delivery systems
David A. Rutolo, Jr., Rancho Santa Margarita, CA (US); Sean Michael Hall, Millers Point (AU); Luis Vitetta, Varsity Lakes (AU); Yusi Zhou, Hornsby (AU); and Samantha Maree Coulson, Fig Tree Pocket (AU)
Assigned to Medlab Clinical U.S., Inc., Rancho Santa Margarita, CA (US)
Filed by Medlab Clinical U.S., Inc., Rancho Santa Margarita, CA (US)
Filed on Oct. 1, 2021, as Appl. No. 17/492,386.
Application 17/492,386 is a continuation of application No. 15/555,038, granted, now 11,160,753, previously published as PCT/US2016/020468, filed on Mar. 2, 2016.
Claims priority of provisional application 62/127,200, filed on Mar. 2, 2015.
Claims priority of provisional application 62/199,007, filed on Jul. 30, 2015.
Prior Publication US 2022/0023199 A1, Jan. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/107 (2006.01); A61K 9/70 (2006.01); A61K 31/05 (2006.01); A61K 31/07 (2006.01); A61K 31/122 (2006.01); A61K 31/135 (2006.01); A61K 31/197 (2006.01); A61K 31/355 (2006.01); A61K 31/375 (2006.01); A61K 31/40 (2006.01); A61K 31/4045 (2006.01); A61K 31/4188 (2006.01); A61K 31/43 (2006.01); A61K 31/4415 (2006.01); A61K 31/505 (2006.01); A61K 31/51 (2006.01); A61K 31/525 (2006.01); A61K 31/565 (2006.01); A61K 31/568 (2006.01); A61K 31/57 (2006.01); A61K 31/573 (2006.01); A61K 31/592 (2006.01); A61K 31/593 (2006.01); A61K 31/675 (2006.01); A61K 31/714 (2006.01); A61K 33/00 (2006.01); A61K 33/06 (2006.01); A61K 33/26 (2006.01); A61K 33/30 (2006.01); A61K 33/32 (2006.01); A61K 33/34 (2006.01); A61K 33/42 (2006.01); A61K 36/185 (2006.01); A61K 38/05 (2006.01); A61K 38/28 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/44 (2017.01)
CPC A61K 9/006 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0043 (2013.01); A61K 9/08 (2013.01); A61K 9/107 (2013.01); A61K 9/7015 (2013.01); A61K 31/05 (2013.01); A61K 31/07 (2013.01); A61K 31/122 (2013.01); A61K 31/135 (2013.01); A61K 31/197 (2013.01); A61K 31/355 (2013.01); A61K 31/375 (2013.01); A61K 31/40 (2013.01); A61K 31/4045 (2013.01); A61K 31/4188 (2013.01); A61K 31/43 (2013.01); A61K 31/4415 (2013.01); A61K 31/505 (2013.01); A61K 31/51 (2013.01); A61K 31/525 (2013.01); A61K 31/565 (2013.01); A61K 31/568 (2013.01); A61K 31/57 (2013.01); A61K 31/573 (2013.01); A61K 31/592 (2013.01); A61K 31/593 (2013.01); A61K 31/675 (2013.01); A61K 31/714 (2013.01); A61K 33/00 (2013.01); A61K 33/06 (2013.01); A61K 33/26 (2013.01); A61K 33/30 (2013.01); A61K 33/32 (2013.01); A61K 33/34 (2013.01); A61K 33/42 (2013.01); A61K 36/185 (2013.01); A61K 38/05 (2013.01); A61K 38/28 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/44 (2013.01)] 19 Claims
 
1. A transmucosal and/or transdermal delivery system, comprising a micelle composition which comprises:
one or more surfactants, wherein the one or more surfactants consist of at least one non-ionic surfactant having a Hydrophile-Lipophile Balance (HLB) value of from about 12 to about 16;
at least one polyol;
at least one active agent;
at least one oil; and
water, at a ratio of said water to the at least one active agent, the at least one non-ionic surfactant and the at least one polyol that is from 4:1 to 1:1 by weight,
and wherein the micelle composition has: (i) a viscosity of from about 5 cP to about 35 cP when measured at 25° C. on a Brookfield viscometer with spindle #1 at 20 rpm; and (ii) an average particle size of from about 5 nm to about 200 nm.